Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant GM-CSF (Plonmarlimab Biosimilar) antibody (Biotin)

This Humanized Monoclonal antibody specifically detects GM-CSF (Plonmarlimab Biosimilar) in ELISA and FACS. It exhibits reactivity toward Human.
Catalog No. ABIN7607848
$211.02
Plus shipping costs $50.00
50 μg
Shipping to: United States
Delivery in 25 to 31 Business Days

Quick Overview for Recombinant GM-CSF (Plonmarlimab Biosimilar) antibody (Biotin) (ABIN7607848)

Target

GM-CSF (Plonmarlimab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 2
  • 1
Humanized

Clonality

  • 2
  • 1
Monoclonal

Conjugate

  • 3
This GM-CSF (Plonmarlimab Biosimilar) antibody is conjugated to Biotin

Application

  • 2
  • 2
  • 1
  • 1
  • 1
ELISA, Flow Cytometry (FACS)

Grade

Research Grade
  • Purpose

    Biotinylated Anti-GM-CSF(plonmarlimab biosimilar) mAb

    Isotype

    IgG1, kappa
  • Application Notes

    ELISA 1:5000-10000, Flow Cyt 1:100

    Comment

    Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Please see Certificate of Analysis for specific instructions of reconstitution.

    Buffer

    Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

    Storage

    -20 °C,-80 °C

    Storage Comment

    Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

    Expiry Date

    12 months
  • Target

    GM-CSF (Plonmarlimab Biosimilar)

    Alternative Name

    plonmarlimab Biosimilar

    Target Type

    Biosimilar

    Background

    Synonyms Target:CSF,CSF2
    Synonyms Antibody:TJ-003234, TJM-2

    UniProt

    P04141
You are here:
Chat with us!